Pasar al contenido principal

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

SAF2016-77541-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synaptic regulator α-synuclein in dopaminergic fibers Is essentially required for the maintenance of subependymal neural stem cells

  • Pérez-Villalba, Ana
  • Sirerol-Piquer, María Salomé
  • Belenguer, Germán
  • Soriano-Cantón, Raúl
  • Muñoz-Manchado, Ana B.
  • Villadiego, Javier
  • Alarcón-Arís, Diana
  • Soria, Federico
  • Dehay, Benjamin
  • Bezard, Erwan
  • Vila, Miquel
  • Bortolozzi, Analía
  • Toledo-Aral, Juan José
  • Pérez-Sánchez, Francisco
  • Fariñas, Isabel
Synaptic protein -synuclein (-SYN) modulates neurotransmission in a complex and poorly understood manner and aggregates in the cytoplasm of degenerating neurons in Parkinsons disease. Here, we report that -SYN present in dopaminergic nigral afferents is essential for the normal cycling and maintenance of neural stem cells (NSCs) in the brain subependymal zone of adult male and female mice. We also showthat premature senescence of adult NSCs into non-neurogenic astrocytes in mice lacking-SYN resemblesthe effects of dopaminergic fiber degeneration resulting from chronic exposure to 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine or intranigral inoculation of aggregated toxic -SYN. Interestingly, NSC loss in -SYN-deficient mice can be prevented by viral delivery of human -SYN into their sustantia nigra or by treatment with L-DOPA, suggesting that -SYN regulates dopamine availability to NSCs. Our data indicatethat-SYN, presentin dopaminergic nerveterminals supplyingthe subependymal zone, acts as a niche componentto sustainthe neurogenic potential of adult NSCs and identify -SYN and DA as potential targets to ameliorate neurogenic defects in the aging and diseased brain., This work was supported by Ministerio de Economía y Competitividad Spanish Grants SAF2014-54581 and SAF2016-77541 and Instituto de Salud Carlos III (PI12/02574, PI13/01390, Centro de Investigacio´n Biome´dica en Red de Enfermedades Neurodegenerativas, Centro de Investigacio´n Biome´dica en Red de Salud Mental and RETIC Tercel)toM.V.,J.J.T-A., A.B., and I.F;Junta de Andalucía(Proyectos de Excelencia)toJ.J.T-A.; Generalitat Valenciana (Programa Prometeo) to I.F.; European Regional Development Fund; and European Union (E.U.) to A.B. R.S.-C. and G.B. received Spanish Ministerio de Educación FPU predoctoral fellowships. Work in the I.F. laboratory is supported by Fundacio´n Botín-Banco Santander., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis

  • Carballo-Carbajal, Iria
  • Laguna, Ariadna
  • Romero-Giménez, Jordi
  • Cuadros, Thais
  • Bové, Jordi
  • Martinez-Vicente, Marta
  • Parent, Annabelle
  • González-Sepúlveda, Marta
  • Peñuelas, Nuria
  • Torra, Albert
  • Rodríguez-Galván, Beatriz
  • Ballabio, Andrea
  • Hasegawa, Takafumi
  • Bortolozzi, Analía
  • Gelpi, Ellen
  • Vila, Miquel
In Parkinson’s disease (PD) there is a selective degeneration of neuromelanin-containing neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin accumulates with age, the latter being the main risk factor for PD. The contribution of neuromelanin to PD pathogenesis remains unknown because, unlike humans, common laboratory animals lack neuromelanin. Synthesis of peripheral melanins is mediated by tyrosinase, an enzyme also present at low levels in the brain. Here we report that overexpression of human tyrosinase in rat substantia nigra results in age-dependent production of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in elderly humans. In these animals, intracellular neuromelanin accumulation above a specific threshold is associated to an age-dependent PD phenotype, including hypokinesia, Lewy body-like formation and nigrostriatal neurodegeneration. Enhancing lysosomal proteostasis reduces intracellular neuromelanin and prevents neurodegeneration in tyrosinase-overexpressing animals. Our results suggest that intracellular neuromelanin levels may set the threshold for the initiation of PD., This work was supported by funds from the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897, to M.V.), Parkinson’s U.K. (to M.V.), Ministry of Economy and Competitiveness (MINECO, Spain) (SAF2016-77541-R and RTC-2014-2812-1, to M.V.), The Michael J. Fox Foundation (U.S.A) (ID15291, to M.V.), La Caixa Banking Foundation (Health Research Project HR17-00513, to M.V.) and CIBERNED (to M.V.). In addition, the Authors would like to acknowledge additional support from the Fundación Tatiana Pérez de Guzmán el Bueno (Spain, to A.L.), Michael J. Fox Foundation (U.S.A.) (ID11580, to A.L.), MINECO (SAF2016-75797-R, to A.Bo.) and FIS-ISCIII-FEDER (PI15/01937 to J.B. and PI13/01390 to A.Bo.). A.L. was the recipient of a post-doctoral fellowship Beatriu de Pinós (2013 BP-DGR B 00043) from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Spain) with co-funding from the Marie Curie COFUND program (E.U.) and a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.). N.P. is the recipient of a predoctoral fellowship FPI (BES-2017-080191) from MINECO (Spain). A.T. is the recipient of a pre-doctoral fellowship PFIS (FI14/00613) from the FIS-ISCIII (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase

  • González-Sepúlveda, Marta
  • Omar, Muhammad Yusof
  • Hamdon, Sally
  • Rosell-Vilar, Santiago
  • Raivio, Noora
  • Abass, Doaa
  • Martínez-Rivas, Anna
  • Vila, Miquel
  • Giraldo, Jesús
  • Carrascal, Montserrat
  • Abián, Joaquín
  • Gil, Carles
  • Sabriá, Josefa
  • Ortiz, Jordi
  • Moreno-Delgado, David
Synaptic events are important to define treatment strategies for brain disorders. In the present paper, freshly obtained rat brain striatal minces were incubated under different times and conditions to determine dopamine biosynthesis, storage, and tyrosine hydroxylase phosphorylation. Remarkably, we found that endogenous dopamine spontaneously accumulated during tissue incubation at 37 °C ex vivo while dopamine synthesis simultaneously decreased. We analyzed whether these changes in brain dopamine biosynthesis and storage were linked to dopamine feedback inhibition of its synthesis-limiting enzyme tyrosine hydroxylase. The aromatic-L-amino-acid decarboxylase inhibitor NSD-1015 prevented both effects. As expected, dopamine accumulation was increased with L-DOPA addition or VMAT2-overexpression, and dopamine synthesis decreased further with added dopamine, the VMAT2 inhibitor tetrabenazine or D auto-receptor activation with quinpirole, accordingly to the known synaptic effects of these treatments. Phosphorylation activation and inhibition of tyrosine hydroxylase on Ser31 and Ser40 with okadaic acid, Sp-cAMP and PD98059 also exerted the expected effects. However, no clear-cut association was found between dopamine feedback inhibition of its own biosynthesis and changes of tyrosine hydroxylase phosphorylation, assessed by Western blot and mass spectrometry. The later technique also revealed a new Thr30 phosphorylation in rat tyrosine hydroxylase. Our methodological assessment of brain dopamine synthesis and storage dynamics ex vivo could be applied to predict the in vivo effects of pharmacological interventions in animal models of dopamine-related disorders., This work was supported by Spanish Government grants SAF2006-08240 (J.O.), SAF2009-12510 (J.O.), SAF2014-58396 (J.G, J.O.), SAF2017-87199-R (J.G, J.O.), SAF2016-77541-R (M.V.), The Michael J. Fox Foundation (ID15291, M.V.), “la Caixa” Foundation (ID 100010434), under the agreement LCF/PR/HR17/52150003 (M.V.). The Biological and Environmental Proteomics laboratory is a member of Proteored-PRB3 and is supported by grant PT17/0019/0008 of the PE I + D + i 2013–2016, funded by ISCIII and FEDER. M.G.S. enjoyed a Spanish government FPI fellowship. G.M received a fellowship from the China Scholarship Council. We thank the skillful technical assistance of Susana Benítez.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Xicoy Cortada, Helena
  • Tolosa, Eduardo
  • Serradell, Mònica
  • Gaig, Carles
  • Vila Bover, Miquel
  • Laguna Tuset, Ariadna
  • Vilas, Dolores
Neurodegeneració; Malaltia de Parkinson; Marcadors predictius, Neurodegeneración; Enfermedad de Parkinson; Marcadores predictivos, Neurodegeneration; Parkinson's disease; Predictive markers, Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia., The study was funded by the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897 to M.V.), Ministerio de Economía y Competitividad (MINECO, Spain) (SAF2015-73997-JIN to A.L. and SAF2016-77541-R to M.V.), Fundació Bancària La Caixa (Junior Leader Fellowship LCF/BQ/PR19/11700005 to A.L. and Health Research Project HR17-00513 to M.V.) and CIBERNED (to M.V. and E.T.). A.L. was the recipient of a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.) and is currently funded by the Junior Leader Program from Fundació Bancària La Caixa (grant LCF/BQ/PR19/11700005). H.X. is the recipient of a Radboud University Personal Ph.D. Grant.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients

  • Recasens, Ariadna
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Parent, Annabelle|||0000-0002-6195-812X
  • Bové, Jordi|||0000-0002-2529-205X
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Tolosa, Eduardo
  • Vila Bover, Miquel|||0000-0002-1352-989X
The online version of this article (10.1186/s40478-018-0509-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial Quality Control in Neurodegenerative Diseases, Focus on Parkinson's Disease and Huntington's Disease

  • Franco Iborra, Sandra|||0000-0001-7385-657X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Perier, Celine|||0000-0001-7446-8173
In recent years, several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease (PD) and Huntington's disease (HD). Despite distinct clinical and pathological features, these two neurodegenerative diseases share critical processes, such as the presence of misfolded and/or aggregated proteins, oxidative stress, and mitochondrial anomalies. Even though the mitochondria are commonly regarded as the "powerhouses" of the cell, they are involved in a multitude of cellular events such as heme metabolism, calcium homeostasis, and apoptosis. Disruption of mitochondrial homeostasis and subsequent mitochondrial dysfunction play a key role in the pathophysiology of neurodegenerative diseases, further highlighting the importance of these organelles, especially in neurons. The maintenance of mitochondrial integrity through different surveillance mechanisms is thus critical for neuron survival. Mitochondria display a wide range of quality control mechanisms, from the molecular to the organellar level. Interestingly, many of these lines of defense have been found to be altered in neurodegenerative diseases such as PD and HD. Current knowledge and further elucidation of the novel pathways that protect the cell through mitochondrial quality control may offer unique opportunities for disease therapy in situations where ongoing mitochondrial damage occurs. In this review, we discuss the involvement of mitochondrial dysfunction in neurodegeneration with a special focus on the recent findings regarding mitochondrial quality control pathways, beyond the classical effects of increased production of reactive oxygen species (ROS) and bioenergetic alterations. We also discuss how disturbances in these processes underlie the pathophysiology of neurodegenerative disorders such as PD and HD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The small GTPase RAC1/CED-10 is essential in maintaining dopaminergic neuron function and survival against α-synuclein-induced toxicity

  • Kim, Hanna
  • Calatayud, Carles|||0000-0003-0032-4198
  • Guha, Sanjib
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Berkowitz, Laura
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Kapahi, Pankaj
  • Raya, Ángel|||0000-0003-2189-9775
  • Miranda Vizuete, Antonio
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Caldwell, Kim A.
  • Caldwell, Guy A.
  • Consiglio, Antonella
  • Dalfo, Esther|||0000-0003-4677-8515
Parkinson's disease is associated with intracellular α-synuclein accumulation and ventral midbrain dopaminergic neuronal death in the Substantia Nigra of brain patients. The Rho GTPase pathway, mainly linking surface receptors to the organization of the actin and microtubule cytoskeletons, has been suggested to participate to Parkinson's disease pathogenesis. Nevertheless, its exact contribution remains obscure. To unveil the participation of the Rho GTPase family to the molecular pathogenesis of Parkinson's disease, we first used C elegans to demonstrate the role of the small GTPase RAC1 (ced-10 in the worm) in maintaining dopaminergic function and survival in the presence of alpha-synuclein. In addition, ced-10 mutant worms determined an increase of alpha-synuclein inclusions in comparison to control worms as well as an increase in autophagic vesicles. We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein. Further, by using dopaminergic neurons derived from patients of familial LRRK2-Parkinson's disease we report that human RAC1 activity is essential in the regulation of dopaminergic cell death, alpha-synuclein.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis

  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Cuadros, Thais|||0000-0001-6994-2424
  • Bové, Jordi|||0000-0002-2529-205X
  • Martinez-Vicente, Marta|||0000-0001-7053-2625
  • Parent, Annabelle|||0000-0002-6195-812X
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Peñuelas, Núria|||0000-0001-6443-9790
  • Torra, Albert|||0000-0002-6852-7146
  • Rodríguez-Galván, Beatriz
  • Ballabio, Andrea|||0000-0003-1381-4604
  • Hasegawa, Takafumi
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Vila Bover, Miquel|||0000-0002-1352-989X
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracellular crowding by age-dependent neuromelanin accumulation disrupts neuronal proteostasis and triggers Parkinson disease pathology

  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
In Parkinson disease (PD), there is a preferential degeneration of neurons that contain the dark-brown cytoplasmic pigment neuromelanin, in particular dopaminergic neurons of the substantia nigra (SN), the loss of which leads to the typical motor symptoms of the disease and constitutes the cardinal pathological diagnostic criterion for PD. Neuromelanin is generally considered a byproduct of dopamine oxidative metabolism and, in humans, it is first detected in early childhood and accumulates progressively with age until occupying most of the neuronal cytoplasm, as neurons apparently lack the means to degrade or eliminate this pigment. Aging is the main risk factor for developing PD, but the molecular substrate underlying this link remains unknown. Despite the close and long-established association between neuromelanin and PD, the potential contribution of neuromelanin to PD pathogenesis has remained elusive because, in contrast to humans, common laboratory animal species, such as rodents, lack neuromelanin. To overcome this major limitation, we have recently generated the first experimental in vivo rodent model exhibiting age-dependent production and accumulation of human-like neuromelanin within PD-vulnerable dopaminergic nigral neurons, at levels up to those reached in elderly humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Laguna, Ariadna|||0000-0002-9732-6677
  • Xicoy, Helena|||0000-0001-6641-1222
  • Tolosa, Eduardo
  • Serradell, Mònica|||0000-0002-2954-3020
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Gaig, Carles|||0000-0002-7113-8125
  • Fernández, Manel
  • Yanes, Oscar|||0000-0003-3695-7157
  • Santamaria Cano, Joan|||0000-0003-0879-4135
  • Amigó, Núria|||0000-0002-0116-9145
  • Iranzo, Alex|||0000-0002-5618-8271
  • Vila Bover, Miquel|||0000-0002-1352-989X
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson's disease

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Novio, Fernando|||0000-0002-1517-3612
  • Nador, Fabiana|||0000-0003-2502-0430
  • Cavaliere, Ivana
  • Suárez García, Salvio|||0000-0002-4156-0579
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Romero-Gimenez, Jordi
  • Rodríguez-Galván, Beatriz
  • Bové, Jordi|||0000-0002-2529-205X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Dopamine (DA) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (DArgic) neurons. A progressive loss of this specific subset of cells is one of the hallmarks of age-related neurodegenerative disorders such as Parkinson's disease (PD). Symptomatic therapy for PD has been centered in the precursor l-DOPA administration, an amino acid precursor of DA that crosses the blood-brain barrier (BBB) while DA does not, although this approach presents medium- to long-term side effects. To overcome this limitation, DA-nanoencapsulation therapies are actively being searched as an alternative for DA replacement. However, overcoming the low yield of encapsulation and/or poor biodistribution/bioavailability of DA is still a current challenge. Herein, we report the synthesis of a family of neuromelanin bioinspired polymeric nanoparticles. Our system is based on the encapsulation of DA within nanoparticles through its reversible coordination complexation to iron metal nodes polymerized with a bis-imidazol ligand. Our methodology, in addition to being simple and inexpensive, results in DA loading efficiencies of up to 60%. In vitro, DA nanoscale coordination polymers (DA-NCPs) exhibited lower toxicity, degradation kinetics, and enhanced uptake by BE(2)-M17 DArgic cells compared to free DA. Direct infusion of the particles in the ventricle of rats in vivo showed a rapid distribution within the brain of healthy rats, leading to an increase in striatal DA levels. More importantly, after 4 days of nasal administrations with DA-NCPs equivalent to 200 μg of the free drug per day, the number and duration of apomorphine-induced rotations was significantly lower from that in either vehicle or DA-treated rats performed for comparison purposes. Overall, this study demonstrates the advantages of using nanostructured DA for DA-replacement therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Defective mitochondrial protein import contributes to complex I-induced mitochondrial dysfunction and neurodegeneration in Parkinson's disease

  • Franco Iborra, Sandra|||0000-0001-7385-657X
  • Cuadros, Thais|||0000-0001-6994-2424
  • Parent, Annabelle|||0000-0002-6195-812X
  • Romero-Gimenez, Jordi
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Perier, Celine|||0000-0001-7446-8173
Mitochondria are the prime energy source in most eukaryotic cells, but these highly dynamic organelles are also involved in a multitude of cellular events. Disruption of mitochondrial homeostasis and the subsequent mitochondrial dysfunction plays a key role in the pathophysiology of Parkinson's disease (PD). Therefore, maintenance of mitochondrial integrity through different surveillance mechanisms is critical for neuronal survival. Here, we have studied the mitochondrial protein import system in in vitro and in vivo models of PD. Complex I inhibition, a characteristic pathological hallmark in PD, impaired mitochondrial protein import, which was associated with a downregulation of two key components of the system: translocase of the outer membrane 20 (TOM20) and translocase of the inner membrane 23 (TIM23), both in vitro and in vivo. In vitro, those changes were associated with OXPHOS protein downregulation, accumulation of aggregated proteins inside mitochondria and downregulation of mitochondrial chaperones. Most of these pathogenic changes, including mitochondrial dysfunction and dopaminergic cell death, were abrogated by TOM20 or TIM23 overexpression, in vitro. However, in vivo, while TOM20 overexpression exacerbated neurodegeneration in both substantia nigra (SN) pars compacta (pc) and striatum, overexpression of TIM23 partially protected dopaminergic neurons in the SNpc. These results highlight mitochondrial protein import dysfunction and the distinct role of two of their components in the pathogenesis of PD and suggest the need for future studies to further characterize mitochondrial protein import deficit in the context of PD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase

  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Omar, Muhammad Yusof|||0000-0003-3414-4777
  • Hamdon, Sally
  • Ma, Guofen
  • Rosell-Vilar, Santi
  • Raivio, Noora|||0000-0003-3425-3228
  • Abass, Doaa|||0009-0003-2520-5790
  • Martínez-Rivas, Anna
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • Gil, Carles|||0000-0003-2976-4146
  • Sabriá, Josefa
  • Ortiz de Pablo, Jordi|||0000-0002-9748-2290
  • Moreno Delgado, David
Synaptic events are important to define treatment strategies for brain disorders. In the present paper, freshly obtained rat brain striatal minces were incubated under different times and conditions to determine dopamine biosynthesis, storage, and tyrosine hydroxylase phosphorylation. Remarkably, we found that endogenous dopamine spontaneously accumulated during tissue incubation at 37 °C ex vivo while dopamine synthesis simultaneously decreased. We analyzed whether these changes in brain dopamine biosynthesis and storage were linked to dopamine feedback inhibition of its synthesis-limiting enzyme tyrosine hydroxylase. The aromatic-l-amino-acid decarboxylase inhibitor NSD-1015 prevented both effects. As expected, dopamine accumulation was increased with l-DOPA addition or VMAT2-overexpression, and dopamine synthesis decreased further with added dopamine, the VMAT2 inhibitor tetrabenazine or D2 auto-receptor activation with quinpirole, accordingly to the known synaptic effects of these treatments. Phosphorylation activation and inhibition of tyrosine hydroxylase on Ser31 and Ser40 with okadaic acid, Sp-cAMP and PD98059 also exerted the expected effects. However, no clear-cut association was found between dopamine feedback inhibition of its own biosynthesis and changes of tyrosine hydroxylase phosphorylation, assessed by Western blot and mass spectrometry. The later technique also revealed a new Thr30 phosphorylation in rat tyrosine hydroxylase. Our methodological assessment of brain dopamine synthesis and storage dynamics ex vivo could be applied to predict the in vivo effects of pharmacological interventions in animal models of dopamine-related disorders.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Xicoy Cortada, Helena
  • Tolosa, Eduardo
  • Serradell, Mònica
  • Gaig, Carles
  • Vila Bover, Miquel
  • Laguna Tuset, Ariadna
  • Vilas, Dolores
Neurodegeneració; Malaltia de Parkinson; Marcadors predictius, Neurodegeneración; Enfermedad de Parkinson; Marcadores predictivos, Neurodegeneration; Parkinson's disease; Predictive markers, Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia., The study was funded by the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897 to M.V.), Ministerio de Economía y Competitividad (MINECO, Spain) (SAF2015-73997-JIN to A.L. and SAF2016-77541-R to M.V.), Fundació Bancària La Caixa (Junior Leader Fellowship LCF/BQ/PR19/11700005 to A.L. and Health Research Project HR17-00513 to M.V.) and CIBERNED (to M.V. and E.T.). A.L. was the recipient of a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.) and is currently funded by the Junior Leader Program from Fundació Bancària La Caixa (grant LCF/BQ/PR19/11700005). H.X. is the recipient of a Radboud University Personal Ph.D. Grant.